## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

OIP	comply w	eotide and/or amino acid sequence disclosure contained in this application does not ith the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the reason(s):
JUN 2	8 2001 E	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
100		<ol> <li>This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).</li> </ol>
		3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
		4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
		5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
		6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
		7. Other:
	Apj	plicant Must Provide:
	Q.	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
		An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	LJ.	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
	For	questions regarding compliance to these requirements, please contact:
		Rules Interpretation, call (703) 308-4216
		CRF Submission Help, call (703) 308-4212
	Pate	entIn Software Program Support (SIRA) Technical Assistance703-287-0200
		To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



RECEIVE

JUL 03 2001

**TECH CENTER 1600/2900** 

BOX SEC # 6/K.7.

Isabelle M. Clauss, Ph.D., J.D. **Boston Office** 617.832.1177 imc@foleyhoag.com

JUN 2 8 2001 PRADEMARY me 25, 2001

**Box Sequence Listing** 

**Assistant Commissioner of Patents** 

Washington, DC 20231

Re:

U.S. Patent Application No.: 09/690,647

Entitled: Methods for Treating and Preventing Insulin Resistance and

Related Disorders

Filed: October 17, 2000 By: Andrew S. Greenberg Atty Ref: TUV-005.01

Dear Sir:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed May 29, 2001 in the above-referenced application, Applicants submit the following:

- Copy of the Notice to Comply with Requirements for Patent Applications 1. Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- Paper copy of Sequence Listing; 2.
- Computer-readable copy of Sequence Listing on diskette; 3.
- Statement Under 37 C.F.R. § § 1.821-1.825; and
- Return receipt postcard.

The Commissioner is hereby authorized to charge any under-payments or credit any over-payments to our Deposit Account No. 06-1448.

## Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Box Sequence Listing, Assistant Commissioner for Patents, Washington, DC 20231 on the date set forth below:

June 25, 2001

Date

Robert King

Respectfully submitted, FOLEY, HOAG & ELIOT LLP

Isabelle M. Clauss, Ph.D.

Reg. No. 47,326

Attorney for Applicants Customer ID No. 25181

20/461992.1